General Cardiology
This research cluster examines the efficacy and role of beta-blocker therapy in secondary prevention after myocardial infarction specifically in patients with preserved or mildly reduced left ventricular ejection fraction.
Sources: 12 new papers · 10 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
Myocardial infarction is defined as the necrosis of the myocardium caused by an obstruction of the blood supply to the heart.1
Based on left ventricular ejection fraction (LVEF) values, post-myocardial infarction patients can be divided into distinct categories for risk stratification, including groups such as LVEF > 40 % , 40 % < LVEF < 50 % , and LVEF ≥ 50 %.1
Beta-blockers have historically served as a cornerstone in secondary prevention following myocardial infarction, but contemporary evidence challenges their long-term use in patients with preserved left ventricular ejection fraction.1 In an analysis of 19,826 post-MI patients, beta-blockers did not reduce time to the primary endpoint (HR 0.92, 95% CI 0.85-1.01; p = 0.08; I 2 = 35%).2 Specifically, in patients with preserved LVEF (≥ 50%), beta-blocker therapy did not significantly reduce the risk of major adverse cardiovascular events (RR 0.96, 95% CI 0.87-1.05).2 A Bayesian meta-analysis of 17,068 patients with LVEF ≥50% evaluated all-cause mortality and reported a posterior risk ratio of 0.79 (95% CrI 0.55-1.06), indicating uncertainty in the magnitude or direction of the effect.3 Consequently, routine long-term beta-blocker prescription may no longer be justified for patients with preserved LVEF (≥50%) without other indications.1
Recent trials presented at the 2025 ESC Congress, along with studies from 2024, have reported conflicting results regarding the role of beta-blockers after myocardial infarction in patients with non-severely reduced ejection fraction.1 It remains to be fully clarified how trial design differences, the timing of treatment relative to the index myocardial infarction, and the specific type and dose of beta-blocker used influence these outcomes.1
FGF13 attenuates myocardial infarction-induced cardiac injury by modulating oxidative stress and NF-κB signaling
Journal of Molecular Histology — Zhang Y — Nov 2026
Predictive value of systemic inflammatory indices for new-onset atrial fibrillation after acute myocardial infarction: an interpretable machine learning study
Annals of Medicine — Meng X — Nov 2026
One class, different indications: Factor XIa inhibition after LIBREXIA-ACS
Med — Palaiodimou L — Nov 2026
Ischaemic stroke and intracerebral haemorrhage in the post-acute phase after myocardial infarction: a nationwide cohort study in Sweden
European Stroke Journal — Ekaputri P — Nov 2026
The Cardioprotective Potential of Red Onion Waste Against Isoprenaline‐Induced Myocardial Infarction in Rat: Molecular Docking and In Vivo Studies
Chemistry & Biodiversity — Mehana N — Nov 2026
Clinical predictive modeling of CK-MB using troponin I/T and CPK in patients post myocardial infarction
Indian Journal of Pharmacology — Alzain M — Nov 2026
Ex Vivo Myocardial Infarction Model in the Crystalloid-Perfused Mouse Heart
Journal of Visualized Experiments — Ouyang W — Oct 2026
Microvascular Obstruction After Reperfusion in ST-Segment Elevation Myocardial Infarction: A Structured Narrative Review
Journal of Visualized Experiments — Long X — Oct 2026
Prediction of coronary events by computed tomography-derived Murray law-based quantitative flow ratio
EuroIntervention — Gim D — Oct 2026
Explainable Machine Learning for Predicting Major Adverse Renal and Cardiovascular Events in Acute Myocardial Infarction With Chronic Kidney Disease: Algorithm Development and Validation
JMIR Medical Informatics — Feng W — Oct 2026
All 17 Beta-Blockers Post-MI with Preserved Ejection Fraction papers →
Efficacy of Beta-blocker Therapy in Post-myocardial Infarction Patients with Preserved or Mildly Reduced Ejection Fraction: A Systematic Review and Meta-analysis
Journal of Cardiac Critical Care TSS — Mata E
Beta-Blocker Therapy After Myocardial Infarction: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials
International Journal of Molecular Sciences — Fusco S
Beta‐Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta‐Analysis With Trial Sequential Analysis
European Journal of Clinical Investigation — Maremmani M
Beta-blockers after myocardial infarction with preserved ejection fraction: A meta-analysis with trial sequential analysis
Journal of the Renin-Angiotensin-Aldosterone System — Song Q
Beta-blockers post myocardial infarction in 2025: time to let it go?
European Heart Journal Acute Cardiovascular Care — Bertaina M
Beta-blockers after myocardial infarction with preserved or mildly reduced ejection fraction: existing evidence, knowledge gaps, and an EF-stratified framework
Frontiers in Pharmacology — Zhao S
Beta-blocker therapy after myocardial infarction with preserved LVEF (≥50%): a systematic review and Bayesian meta-analysis with time-to-event reconstruction
American Heart Journal Plus Cardiology Research and Practice — Al-Shammari A
Baseline Ejection Fraction as a Modifier of Beta‐Blocker Therapeutic Effects in Post‐Acute Coronary Syndrome Patients With Non‐Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis
Cardiovascular Therapeutics — Mirhosseini S
Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction
New England Journal of Medicine — Kristensen A
Guideline implications of REBOOT: beta-blockers therapy in post-MI patients with preserved LVEF
International Journal of Surgery — Nazir A
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.